A novel reactor configuration for continuous virus inactivation
Authors:
- Nikhil KatejaNKNikhil Kateja
- Nitika NitikaNNNitika Nitika
- Rahul S. FadnisRFRahul S. Fadnis
- Anurag S. RathoreARAnurag S. Rathore
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 167
Abstract
No abstract availableKeywords
Funding Information
- Council of Scientific and Industrial Research, India (09/086(1363)/2019-EMR-1)
- Department of Biotechnology, Ministry of Science and Technology, India (BT/COE/34/SP15097/2015)
- Department of Biotechnology, Ministry of Science and Technology, India (DBT/2018/IIT-D/1055)
- Ministry of Education, India (21-105/2015-TS.II/TC)
This publication has 26 references indexed in Scilit:
- Biopharmaceutical benchmarks 2018Nature Biotechnology, 2018
- Non-protein A purification platform for continuous processing of monoclonal antibody therapeuticsJournal of Chromatography A, 2018
- Integrated continuous processing of proteins expressed as inclusion bodies: GCSF as a case studyBiotechnology Progress, 2017
- Continuous viral inactivation at low pH value in antibody manufacturingChemical Engineering and Processing - Process Intensification, 2016
- End-to-end integrated fully continuous production of recombinant monoclonal antibodiesJournal of Biotechnology, 2015
- Continuous Processing for Production of BiopharmaceuticalsPreparative Biochemistry & Biotechnology, 2014
- Economics of recombinant antibody production processes at various scales: Industry‐standard compared to continuous precipitationBiotechnology Journal, 2014
- Integrated continuous production of recombinant therapeutic proteinsBiotechnology and Bioengineering, 2012
- Downstream processing of monoclonal antibodies—Application of platform approachesJournal of Chromatography B, 2007
- The clearance of viruses and transmissible spongiform encephalopathy agents from biologicalsCurrent Opinion in Biotechnology, 2005